WASHINGTON, Aug. 12 -- National Institutes of Health has issued a notice called: Government Owned Invention Available for License: Human Antibodies Targeting Beneficial Viral Peptide in Liver Cancer.
The notice was published in the Federal Register on Aug. 12 by Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute.
Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees to develop a collection of anti-CE1 antibodies for liver cancer treatment.
For more information, contact Inquiries related to this license opportunity should be directed to: Michael Pollack, Ph.D, Unit Supervisor, NCI, Technology Transfer Center, Email: PollackM@mail.nih.govor Phone: 2...